[1]
Nigam PK, Nigam A. Botulinum toxin. Indian journal of dermatology. 2010:55(1):8-14. doi: 10.4103/0019-5154.60343. Epub
[PubMed PMID: 20418969]
[2]
Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. Journal of the American Academy of Dermatology. 2005 Sep:53(3):407-15
[PubMed PMID: 16112345]
Level 3 (low-level) evidence
[2]
Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2000 Sep:7(5):389-94
[PubMed PMID: 10942658]
[3]
Patel KB, Cai S, Adler M, Singh BK, Parmar VS, Singh BR. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin. Applied and environmental microbiology. 2018 Dec 15:84(24):. doi: 10.1128/AEM.01280-18. Epub 2018 Nov 30
[PubMed PMID: 30389764]
[5]
Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Current pain and headache reports. 2016 Mar:20(3):15. doi: 10.1007/s11916-016-0545-0. Epub
[PubMed PMID: 26879873]
[6]
Park J, Park HJ. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins. 2017 Aug 24:9(9):. doi: 10.3390/toxins9090260. Epub 2017 Aug 24
[PubMed PMID: 28837075]
[8]
Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. The Journal of clinical and aesthetic dermatology. 2014 Feb:7(2):31-9
[PubMed PMID: 24587850]
Level 3 (low-level) evidence
[9]
Godoy IR, Donahue DM, Torriani M. Botulinum Toxin Injections in Musculoskeletal Disorders. Seminars in musculoskeletal radiology. 2016 Nov:20(5):441-452. doi: 10.1055/s-0036-1594284. Epub 2016 Dec 21
[PubMed PMID: 28002866]
[10]
Luvisetto S, Gazerani P, Cianchetti C, Pavone F. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders. Toxins. 2015 Sep 23:7(9):3818-44. doi: 10.3390/toxins7093818. Epub 2015 Sep 23
[PubMed PMID: 26404377]
[11]
Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arquivos de neuro-psiquiatria. 2005 Mar:63(1):180-5
[PubMed PMID: 15830090]
[11]
Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon : official journal of the International Society on Toxinology. 2015 Dec 1:107(Pt A):77-84. doi: 10.1016/j.toxicon.2015.08.001. Epub 2015 Aug 7
[PubMed PMID: 26260691]
[12]
Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: bioweapon & magic drug. The Indian journal of medical research. 2010 Nov:132(5):489-503
[PubMed PMID: 21149997]
[13]
Small R. Botulinum toxin injection for facial wrinkles. American family physician. 2014 Aug 1:90(3):168-75
[PubMed PMID: 25077722]
[14]
Zakin E, Simpson D. Evidence on botulinum toxin in selected disorders. Toxicon : official journal of the International Society on Toxinology. 2018 Jun 1:147():134-140. doi: 10.1016/j.toxicon.2018.01.019. Epub 2018 Feb 3
[PubMed PMID: 29408357]
[15]
Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Snyder D, Foster K. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins. 2018 Dec 13:10(12):. doi: 10.3390/toxins10120535. Epub 2018 Dec 13
[PubMed PMID: 30551641]
[16]
Kattimani V, Tiwari RVC, Gufran K, Wasan B, Shilpa PH, Khader AA. Botulinum Toxin Application in Facial Esthetics and Recent Treatment Indications (2013-2018). Journal of International Society of Preventive & Community Dentistry. 2019 Mar-Apr:9(2):99-105. doi: 10.4103/jispcd.JISPCD_430_18. Epub 2019 Apr 12
[PubMed PMID: 31058058]
[18]
Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K, Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001 Feb 28:285(8):1059-70
[PubMed PMID: 11209178]
[19]
Khouri JM, Motter RN, Arnon SS. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. Vaccine. 2018 Apr 5:36(15):2041-2048. doi: 10.1016/j.vaccine.2018.02.042. Epub 2018 Feb 21
[PubMed PMID: 29475762]
[20]
Castelão M, Marques RE, Duarte GS, Rodrigues FB, Ferreira J, Sampaio C, Moore AP, Costa J. Botulinum toxin type A therapy for cervical dystonia. The Cochrane database of systematic reviews. 2017 Dec 12:12(12):CD003633. doi: 10.1002/14651858.CD003633.pub3. Epub 2017 Dec 12
[PubMed PMID: 29230798]
Level 1 (high-level) evidence
[21]
Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, Clarke CE, Sinclair A. Botulinum toxins for the prevention of migraine in adults. The Cochrane database of systematic reviews. 2018 Jun 25:6(6):CD011616. doi: 10.1002/14651858.CD011616.pub2. Epub 2018 Jun 25
[PubMed PMID: 29939406]
Level 1 (high-level) evidence
[22]
Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012 Apr 25:307(16):1736-45. doi: 10.1001/jama.2012.505. Epub
[PubMed PMID: 22535858]
Level 1 (high-level) evidence
[23]
Jia Z, Lu H, Yang X, Jin X, Wu R, Zhao J, Chen L, Qi Z. Adverse Events of Botulinum Toxin Type A in Facial Rejuvenation: A Systematic Review and Meta-Analysis. Aesthetic plastic surgery. 2016 Oct:40(5):769-77. doi: 10.1007/s00266-016-0682-1. Epub 2016 Aug 5
[PubMed PMID: 27495260]
Level 2 (mid-level) evidence